The milestone payment was triggered by the first commercial sale of DARZALEX in Europe. The European Commission (EC) recently granted a conditional marketing authorization for first-in-class CD38 immunotherapy DARZALEX (daratumumab) for use as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor (PI) and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.
Catalyst
Slingshot members are tracking this event:
Genmab Achieves USD 30 Million Milestone in DARZALEX (daratumumab) Collaboration with Janssen
Do you think this event is important to the companies below? How will it affect their stock price?
Additional Information
The milestone payment was triggered by the first commercial sale of DARZALEX in Europe. The European Commission (EC) recently granted a conditional marketing authorization for first-in-class CD38 immunotherapy DARZALEX (daratumumab) for use as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor (PI) and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 30, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Darzalex, Daratumumab
